A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction

Phase 2 Terminated 34 enrolled Lisata Therapeutics, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This clinical trial will explore the efficacy and safety of GCSF-mobilized autologous CD34+ cells for the treatment of CMD in adults currently experiencing angina and with no obstructive coronary artery disease. Eligible subjects will receive a single administration of CLBS16 or placebo.

Timeline

Start: 2020-10-29
Primary completion: 2022-09-28
Completion: 2022-09-28

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision”

Publications

Rai B, Shukla J, Henry TD, Quesada O. Angiogenic CD34 Stem Cell Therapy in Coronary Microvascular Repair-A Systematic Review. Cells. 2021 May 8;10(5):1137. doi: 10.3390/cells10051137.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CLBS16	Cell therapy	—	—